307 related articles for article (PubMed ID: 30802512)
1. Linarin improves the dyskinesia recovery in Alzheimer's disease zebrafish by inhibiting the acetylcholinesterase activity.
Pan H; Zhang J; Wang Y; Cui K; Cao Y; Wang L; Wu Y
Life Sci; 2019 Apr; 222():112-116. PubMed ID: 30802512
[TBL] [Abstract][Full Text] [Related]
2. Aaptamine - a dual acetyl - and butyrylcholinesterase inhibitor as potential anti-Alzheimer's disease agent.
Miao S; He Q; Li C; Wu Y; Liu M; Chen Y; Qi S; Gong K
Pharm Biol; 2022 Dec; 60(1):1502-1510. PubMed ID: 35968601
[TBL] [Abstract][Full Text] [Related]
3. Linarin Inhibits the Acetylcholinesterase Activity In-vitro and Ex-vivo.
Feng X; Wang X; Liu Y; Di X
Iran J Pharm Res; 2015; 14(3):949-54. PubMed ID: 26330885
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
5. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents.
Pandey S; Singh BK
Curr Comput Aided Drug Des; 2020; 16(1):54-72. PubMed ID: 30827255
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Son M; Park C; Rampogu S; Zeb A; Lee KW
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
[TBL] [Abstract][Full Text] [Related]
7. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
8. Combining in silico and in vitro approaches to evaluate the acetylcholinesterase inhibitory profile of some commercially available flavonoids in the management of Alzheimer's disease.
Kuppusamy A; Arumugam M; George S
Int J Biol Macromol; 2017 Feb; 95():199-203. PubMed ID: 27871793
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
Ambure P; Kar S; Roy K
Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.
Liu S; Shang R; Shi L; Zhou R; He J; Wan DC
Chem Biol Drug Des; 2014 Aug; 84(2):169-74. PubMed ID: 24890706
[TBL] [Abstract][Full Text] [Related]
11. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease.
Iman K; Mirza MU; Mazhar N; Vanmeert M; Irshad I; Kamal MA
CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):54-68. PubMed ID: 29336270
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy.
Rizvi SM; Shaikh S; Naaz D; Shakil S; Ahmad A; Haneef M; Abuzenadah AM
Neurochem Res; 2016 Jun; 41(6):1475-82. PubMed ID: 26886763
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease.
Atukeren P; Cengiz M; Yavuzer H; Gelisgen R; Altunoglu E; Oner S; Erdenen F; Yuceakın D; Derici H; Cakatay U; Uzun H
Biomed Pharmacother; 2017 Jun; 90():786-795. PubMed ID: 28427041
[TBL] [Abstract][Full Text] [Related]
14. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease.
Zhou A; Hu J; Wang L; Zhong G; Pan J; Wu Z; Hui A
J Mol Model; 2015 Oct; 21(10):277. PubMed ID: 26438408
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
[TBL] [Abstract][Full Text] [Related]
16. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B; Singh N
Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
[TBL] [Abstract][Full Text] [Related]
17. The inefficacy of donepezil on glycated-AChE inhibition: Binding affinity, complex stability and mechanism.
Yekta R; Sadeghi L; Dehghan G
Int J Biol Macromol; 2020 Oct; 160():35-46. PubMed ID: 32454110
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.
Deb PK; Sharma A; Piplani P; Akkinepally RR
Mol Divers; 2012 Nov; 16(4):803-23. PubMed ID: 22996404
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
20. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's.
Dhanjal JK; Sharma S; Grover A; Das A
Biomed Pharmacother; 2015 Apr; 71():146-52. PubMed ID: 25960230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
